2024-10-22 12:58 | CC:CRDL | Cardiol Therapeutics Inc | 2.64 | News Release200 | Cardiol plans late-stage clinical trial for CardiolRx |
2024-10-11 13:28 | CC:CRDL | Cardiol Therapeutics Inc | 2.46 | News Release200 | Cardiol Therapeutics issues 1.26 M shares in greenshoe |
2024-10-10 16:40 | CC:CRDL | Cardiol Therapeutics Inc | 2.46 | News Release200 | Cardiol closes $13.5-million (U.S.) public offering |
2024-10-09 21:12 | CC:CRDL | Cardiol Therapeutics Inc | 2.53 | Prospectus Approved3 | Cardiol to list 8,437,500 more shares Oct. 10 |
2024-10-09 11:00 | CC:CRDL | Cardiol Therapeutics Inc | 2.69 | News Release200 | Cardiol Therapeutics prices $13.5M (U.S.) offering |
2024-10-08 17:58 | CC:CRDL | Cardiol Therapeutics Inc | 2.69 | News Release200 | Cardiol Therapeutics gets ready to make share offering |
2024-09-24 10:51 | CC:CRDL | Cardiol Therapeutics Inc | 3.12 | News Release200 | Cardiol hits target patient enrolment in Archer trial |
2024-09-10 15:12 | CC:CRDL | Cardiol Therapeutics Inc | 2.68 | News Release200 | Cardiol completes phase II study on CardiolRx |
2024-08-12 16:55 | CC:CRDL | Cardiol Therapeutics Inc | 2.77 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2024-08-12 16:55 | CC:CRDL | Cardiol Therapeutics Inc | 2.77 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
2024-07-05 14:47 | CC:CRDL | Cardiol Therapeutics Inc | 2.70 | SEDAR Final Short Form Prospectus810 | SEDAR Final Short Form Prospectus |
2024-07-05 12:36 | CC:CRDL | Cardiol Therapeutics Inc | 2.70 | SEDAR Preliminary Short Form Prospectus819 | SEDAR Preliminary Short Form Prospectus |
2024-06-27 16:39 | CC:CRDL | Cardiol Therapeutics Inc | 2.74 | News Release200 | Cardiol Therapeutics holders approve AGM resolutions |
2024-06-25 11:37 | CC:CRDL | Cardiol Therapeutics Inc | 2.89 | News Release200 | Cardiol to webcast virtual AGSM June 26 |
2024-06-13 12:27 | CC:CRDL | Cardiol Therapeutics Inc | 4.07 | News Release200 | Cardiol Therapeutics reviews CardiolRx study data |
2024-05-14 17:07 | CC:CRDL | Cardiol Therapeutics Inc | 2.95 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2024-05-14 17:07 | CC:CRDL | Cardiol Therapeutics Inc | 2.95 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
2024-04-17 13:49 | CC:CRDL | Cardiol Therapeutics Inc | 2.415 | Warrants Expire110 | Cardiol Therapeutics warrants to expire May 13 |
2024-04-02 09:26 | CC:CRDL | Cardiol Therapeutics Inc | 2.58 | News Release200 | Cardiol Therapeutics recaps 2023 operations |
2024-04-01 19:04 | CC:CRDL | Cardiol Therapeutics Inc | 2.58 | SEDAR Annual Report803 | SEDAR Annual Report |
2024-04-01 18:57 | CC:CRDL | Cardiol Therapeutics Inc | 2.58 | SEDAR MD & A815 | SEDAR MD & A |
2024-04-01 18:45 | CC:CRDL | Cardiol Therapeutics Inc | 2.58 | SEDAR Audited Annual Financial Statements804 | SEDAR Audited Annual Financial Statements |
2024-02-21 11:23 | CC:CRDL | Cardiol Therapeutics Inc | 2.25 | News Release200 | Cardiol completes patient enrolment for CardiolRx study |
2024-02-15 09:28 | CC:CRDL | Cardiol Therapeutics Inc | 1.42 | News Release200 | Cardiol receives orphan drug designation for CardiolRx |
2024-01-24 11:08 | CC:CRDL | Cardiol Therapeutics Inc | 1.52 | News Release200 | Cardiol regains Nasdaq listing standard compliance |
2024-01-09 11:35 | CC:CRDL | Cardiol Therapeutics Inc | 1.36 | News Release200 | Cardiol enrolls over 50% of patients in Archer study |
2023-12-05 11:11 | CC:CRDL | Cardiol Therapeutics Inc | 1.29 | News Release200 | Cardiol adds Mass. General Hospital to CardiolRx study |
2023-11-16 09:18 | CC:CRDL | Cardiol Therapeutics Inc | 1.14 | News Release200 | Cardiol presents CardiolRx study results at MPD2023 |
2023-11-14 16:45 | CC:CRDL | Cardiol Therapeutics Inc | 1.19 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
2023-11-14 16:41 | CC:CRDL | Cardiol Therapeutics Inc | 1.19 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |